Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBIO001
- Development stage
- Preclinical
- Lead developer
- Tailor Biosciences
- Modality
- Small Molecules
01
Overview
TBIO001 is a preclinical-stage small molecule therapeutic being developed by Tailor Biosciences for the treatment of solid tumors. It operates through a synthetic lethal mechanism of action, specifically targeting the cell cycle response pathway. The drug is designed to exploit chromosomal instability (CIN) in cancer cells. Its development is integrated with a companion diagnostic, TBIO001 CDx, which utilizes a CIN-based biomarker to identify patient populations most likely to benefit from the treatment. As of 2024, the program is in the candidate selection stage of preclinical development.
- Other names
- TBIO001TBIO-001TBIO 001
Beyond the preview
Go deeper on TBIO001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBIO001.